Analyst Consensus ?
ConsensusHold18 ratings
Bullish844.4%
Neutral1055.6%
Bearish00.0%
1 unmapped firm rating excluded from the percentages.
Mettler-Toledo International Inc. · MTD · FY2024 Q4 · Calendar Q1 2025
Mettler-Toledo transcript points to strong demand, measured 2025 outlook
The supplied analysis offers evidence for a constructive but not unqualified outlook: strong Q4 laboratory and product-inspection performance, pricing and productivity gains, and service and automation initiatives support continued earnings growth. The case remains dependent on demand normalization in China and industrial markets, while currency, tariff and shipping risks could temper near-term progress.
Reported After market closeNYSEHealthcare
$32.57B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $11.76
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $1.01B
Revenue surprise
—
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
-1.9%
Event window
SPY move
-0.0%
Same window
Abnormal move
-1.9%
Stock minus SPY
Volume
0.8×
Versus trailing sessions
Subsequent drift
-2.9%
Up to 20 sessions
MTDSPY benchmark
Ask FN2 about MTD FY2024 Q4
Transcript, numbers and history already loaded
What drove MTD's -1.9% move after FY2024 Q4 earnings?What changed in MTD's guidance and outlook in FY2024 Q4?Give me the bull and bear case for MTD after FY2024 Q4 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, the narrative shifted from uneven segment performance and China uncertainty to a stronger Q4 led by laboratory and product inspection. Management’s 2025 sales-growth outlook remained near 3%, EPS guidance moved modestly higher, and the company emphasized Spinnaker 6, Blue Ocean and SternDrive as execution priorities.
Guidance delta
2025 sales-growth guidance stayed near 3%, while EPS guidance was raised modestly; operating-margin expectations remained flat to slightly higher.
Key takeaways
- The supplied transcript analysis describes Q4 2024 double-digit sales growth and record adjusted EPS.
- Laboratory sales were described as up 18%, with product inspection up 12%.
- Higher volumes, positive price realization and productivity lifted gross margin by 220 basis points.
- The growth case rests on automation, digitalization, service expansion and demand from pharma and biopharma.
Management priorities
- Launch Spinnaker 6 with expanded analytics for sales enablement.
- Use Blue Ocean SAP harmonization to improve real-time business intelligence.
- Advance SternDrive automation and digitalization initiatives.
- Expand service capacity, service contracts and growth efforts in India, Japan and other emerging markets.
Follow MTD with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$1,625.73Previous close
$1,100Low
$1,437.25Average
$1,700High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Oct 20, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Oct 13, 2026 |
| Barclays | Overweight | Overweight | Maintain | Oct 7, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Aug 3, 2026 |
| Stifel | Buy | Buy | Maintain | Aug 3, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Aug 3, 2026 |
| Jefferies | Buy | Buy | Maintain | Jul 31, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | May 11, 2026 |
| Baird | Neutral | Neutral | Maintain | May 11, 2026 |
| Citigroup | Buy | Buy | Maintain | May 8, 2026 |
| B of A Securities | Neutral | Neutral | Maintain | Sep 22, 2025 |
| UBS | Buy | Neutral | Upgrade | May 20, 2025 |
| Goldman Sachs | Neutral | Neutral | Maintain | Jul 9, 2024 |
| CFRA | Hold | Hold | Maintain | May 8, 2020 |
| Bank of America | Neutral | Buy | Downgrade | Jan 3, 2019 |
| Deutsche Bank | Hold | Hold | Maintain | May 4, 2018 |
| Cantor Fitzgerald | Buy | Buy | Maintain | Jul 28, 2014 |
| Credit Agricole | Outperform | Underperform | Upgrade | Feb 7, 2013 |
| CL King | Neutral | Buy | Downgrade | Dec 19, 2012 |
| ISI Group | Underweight | Upgrade | Jul 27, 2012 |
Named analyst price targets
Upside is calculated against the persisted previous close $1,625.73. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Morgan Stanley | Analyst unavailable | $1,575 | $1,560.98 | -3.1% | Oct 12, 2026 |
| Barclays | Analyst unavailable | $1,700 | $1,533.07 | +4.6% | Oct 7, 2026 |
| RBC Capital | Dan Leonard | $1,515 | $1,405.14 | -6.8% | Sep 1, 2026 |
| Morgan Stanley | Kallum Titchmarsh | $1,450 | $1,433.89 | -10.8% | Aug 4, 2026 |
| Barclays | Analyst unavailable | $1,575 | $1,416.3 | -3.1% | Aug 3, 2026 |
| Stifel Nicolaus | Daniel Arias | $1,600 | $1,416.3 | -1.6% | Aug 3, 2026 |
| Jefferies | Analyst unavailable | $1,580 | $1,412.91 | -2.8% | Jul 31, 2026 |
| Evercore ISI | Analyst unavailable | $1,350 | $1,292.74 | -17.0% | Jul 6, 2026 |
| Stifel Nicolaus | Daniel Arias | $1,400 | $1,031.64 | -13.9% | May 18, 2026 |
| Robert W. Baird | Analyst unavailable | $1,194 | $1,124.46 | -26.6% | May 11, 2026 |
| Barclays | Analyst unavailable | $1,500 | $1,345.89 | -7.7% | Apr 14, 2026 |
| Morgan Stanley | Kallum Titchmarsh | $1,475 | $1,382.72 | -9.3% | Feb 9, 2026 |
| Robert W. Baird | Catherine Ramsey Schulte | $1,445 | $1,373.57 | -11.1% | Feb 9, 2026 |
| Wells Fargo | Analyst unavailable | $1,450 | $1,393.64 | -10.8% | Dec 15, 2025 |
| Susquehanna | Analyst unavailable | $1,600 | $1,393.64 | -1.6% | Dec 15, 2025 |
| Barclays | Analyst unavailable | $1,550 | $1,393.64 | -4.7% | Dec 15, 2025 |
| Goldman Sachs | Analyst unavailable | $1,475 | $1,381.37 | -9.3% | Dec 9, 2025 |
| Morgan Stanley | Kallum Titchmarsh | $1,550 | $1,468.09 | -4.7% | Dec 1, 2025 |
| Evercore ISI | Analyst unavailable | $1,400 | $1,345.27 | -13.9% | Oct 7, 2025 |
| Barclays | Analyst unavailable | $1,350 | $1,289.82 | -17.0% | Oct 2, 2025 |
| Barclays | Analyst unavailable | $1,325 | $1,185.18 | -18.5% | Jun 24, 2025 |
| UBS | Dan Leonard | $1,350 | $1,159.1 | -17.0% | May 19, 2025 |
| Jefferies | Tycho Peterson | $1,100 | $1,100.01 | -32.3% | May 4, 2025 |
| Robert W. Baird | Analyst unavailable | $1,034 | $1,003.16 | -36.4% | Apr 22, 2025 |
| Stifel Nicolaus | Daniel Arias | $1,450 | $1,378.34 | -10.8% | Nov 11, 2024 |
| Stifel Nicolaus | Daniel Arias | $1,550 | $1,441.43 | -4.7% | Aug 5, 2024 |
| Robert W. Baird | Catherine Schulte | $1,375 | $1,441.43 | -15.4% | Aug 5, 2024 |
| Jefferies | Tycho Peterson | $1,250 | $1,404.09 | -23.1% | Jun 3, 2024 |
| Stifel Nicolaus | Daniel Arias | $1,510 | $1,510.25 | -7.1% | May 13, 2024 |
| Robert W. Baird | Catherine Schulte | $1,360 | $1,449.38 | -16.3% | May 13, 2024 |
| Stifel Nicolaus | Daniel Arias | $1,500 | $1,195.02 | -7.7% | Sep 6, 2022 |
| UBS | Elizabeth Garcia | $1,237 | $1,349.73 | -23.9% | Jul 31, 2022 |
| Wells Fargo | Analyst unavailable | $1,410 | $1,284.63 | -13.3% | Apr 25, 2022 |
Track every rating change on MTD the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationMettler-Toledo International Inc. (MTD) is a global enterprise dedicated to the production and provision of precision instruments and related services. The company's operations are strategically organized across five geographical divisions: its domestic U.S. market, Swiss operations, Western European activities, Chinese operations, and an 'Other' segment covering remaining territories. Their extensive product portfolio serves diverse scientific and industrial needs. Within the laboratory sphere, Mettler-Toledo supplies a comprehensive array of equipment, including high-precision balances, advanced liquid handling systems (such as pipetting solutions), automated laboratory reactors, titrators, pH meters, sensors and analyzers for process analytics, instruments for evaluating physical properties, thermal analysis systems, and various other analytical tools. These hardware offerings are complemented by LabX, their proprietary software platform designed for managing and analyzing instrument-generated data.…
Historical context
All MTD earningsLatest beats and misses
Who reports nextBeat on EPS
Missed on EPS
Get the MTD recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-01-30T00:03:07.291072+00:00
- Polygon adjusted daily market bars · 2026-10-20T08:40:47.162605+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-20T08:40:47.159822+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-20. For educational purposes only; not investment advice.